# Cinacalcet (Sensipar) Guideline

## Secondary Hyperparathyroidism due to Chronic Kidney Disease on Dialysis:
- Member is at least 18 years of age
- Serum calcium greater than or equal to 8.4mg/dL, prior to initiation of therapy
- Intact parathyroid hormone (iPTH) greater than or equal to 300pg/mL, prior to initiation of therapy
- Inadequate response or intolerable side effect to at least one type of phosphate binder
- Member meets one of the following criteria:
  - Inadequate response or intolerable side effect to calcitriol or paricalcitol
  - Serum phosphate greater than or equal to 5.5mg/dL, or serum calcium greater than or equal to 9.5mg/dL, and there is persistently elevated parathyroid hormone (PTH), despite maximum therapies to decrease phosphate

## Parathyroid Cancer:
- Member is at least 18 years of age
- Serum calcium is greater than or equal to 12.5mg/dL, prior to initiation of therapy

## Primary Hyperparathyroidism:
- Member is at least 18 years of age
- Member is not a candidate for parathyroidectomy
- Serum calcium greater than or equal to 12.5mg/dL, prior to initiation of therapy

## Duration of Approval if Requirements Are Met:

### Initial Approval:
- 6 months

### Renewal Approval:
- 1 year

### Requires:
- Serum Calcium 8.4-12.5mg/dL

### Dosing information:
- **Dialysis member with secondary hyperparathyroidism:** Up to 300 mg/day
- **Hypercalcemia associated with parathyroid carcinoma or primary hyperparathyroidism:** Up to 360 mg/day

---

**Sensipar References:**